The Patient and Caregiver courses teach the universal core — consent, readiness, mindset, integration, safety — that's true no matter which medicine. This library adds the medicine-specific half: a plain-language brief for each modality, so a veteran preparing for ketamine or MDMA is served just as honestly as one preparing for ibogaine.
The full landscape, organized by class — this is what "the standard for everything" covers, and how any future medicine slots in.
| Medicine | Being explored for | Legal status (US) | Signature risk |
|---|---|---|---|
| Classic psychedelics (serotonergic, 5-HT2A) | |||
| Psilocybin | Depression, alcohol use, PTSD, end-of-life distress | Schedule I (trials; some state programs) | Psychological (psychosis/bipolar); transient BP/HR |
| LSD | Anxiety, depression | Schedule I | Very long duration; psychological; HPPD |
| DMT / Ayahuasca | Depression, trauma | Schedule I (some religious exemptions) | Rapid intensity; cardiovascular; ayahuasca is an MAOI (major interactions) |
| 5-MeO-DMT | Depression, addiction | Schedule I | Extreme intensity; physical/airway safety |
| Mescaline (peyote/San Pedro) | Trauma, addiction | Schedule I (peyote exemptions) | Long duration; cardiovascular |
| Entactogens / empathogens | |||
| MDMA | PTSD | Schedule I (late-stage trials) | Serotonin syndrome; hyperthermia; hyponatremia |
| Dissociatives (NMDA antagonists) | |||
| Ketamine / Esketamine | Depression, suicidality, PTSD | Schedule III (ketamine off-label; esketamine FDA-approved) | Bladder toxicity; dependence; dissociation; BP |
| Oneirogen / iboga alkaloids | |||
| Ibogaine | Opioid/other addiction, TBI, PTSD | Schedule I | Cardiac — QT prolongation, fatal arrhythmia |
| Cannabinoids | |||
| Cannabis (THC/CBD) | PTSD, pain, sleep | Schedule I federally; many states legal | Dose-dependent psychosis; cardiovascular; dependence |
| Atypical plant / opioid-adjacent | |||
| Kratom (mitragynine) | Opioid withdrawal, pain, mood | Unscheduled federally; varies by state | Dependence/withdrawal; hepatotoxicity; toxicity |
A plant-derived compound that acts on many brain systems at once and raises BDNF (a growth signal for neurons)3; used mainly for addiction and, increasingly, TBI/PTSD in veterans1.
A Stanford study of 30 Special Operations veterans reported large improvements in disability, PTSD, depression, and anxiety — striking, but early and open-label1.
Its defining danger is the heart: it prolongs the QT interval and can cause fatal arrhythmia, at normal doses, even without prior heart disease, with risk lasting days2,3,4. Your body's CYP2D6 enzyme also determines your exposure — some people get double the dose effect5.
A compound that increases serotonin and promotes feelings of safety and connection, studied primarily to help people process trauma in PTSD therapy.
It appears to lower fear and defensiveness enough to make trauma processing possible; late-stage trials have targeted PTSD.
Because it floods serotonin, combining it with SSRIs, SNRIs, or MAOIs risks serotonin syndrome — a medical emergency. It can also cause dangerous overheating, low sodium from over-drinking water, and raises blood pressure/heart rate6.
An anesthetic at higher doses; at lower doses it produces a dissociative state and rapidly boosts neuroplasticity, used for depression, suicidality, and PTSD. Esketamine (a nasal form) is FDA-approved for treatment-resistant depression.
It can lift severe depression and suicidal thinking quickly — sometimes within hours — which is why it's the most medically accessible of these options.
Acute dissociation and a temporary rise in blood pressure/heart rate. With repeated or frequent use, two concerns grow: bladder damage ("ketamine cystitis")7 and dependence/abuse potential.
The active compound in "magic mushrooms," which acts on serotonin 5-HT2A receptors and promotes neuroplasticity; studied for depression, alcohol use, PTSD, and end-of-life distress.
Controlled trials show real benefit — for example, a randomized trial in alcohol use disorder found significantly fewer heavy-drinking days, with no serious adverse events from psilocybin8.
Medical risk in controlled settings is relatively low8,10, but the psychological risk is real — it can destabilize people with a history of psychosis or bipolar disorder — and it transiently raises blood pressure/heart rate6. Rarely, lingering visual changes (HPPD) occur10.
A potent, long-acting serotonergic psychedelic studied for anxiety and depression; mechanism is similar to psilocybin but the experience lasts much longer (up to ~12 hours).
Medical toxicity is generally low in controlled settings, but the very long duration magnifies psychological demand; risks include destabilization in vulnerable people, HPPD, and transient high blood pressure10.
Acts on the body's cannabinoid system; THC is intoxicating, CBD is not. Used by many veterans for PTSD symptoms, pain, and sleep — legally in many states, though evidence for PTSD specifically is still limited.
The clearest risk is psychosis: reviews show a dose-dependent increased risk, earlier onset, and worse course — especially in those with a personal or family predisposition9. Also: increased heart rate/cardiovascular strain, dependence, and, with heavy chronic use, cannabinoid hyperemesis.
A Southeast Asian plant whose alkaloids act partly on opioid receptors; often self-used for opioid withdrawal, pain, and mood. It is not a psychedelic — but it's widely used in this same population, so honest education matters.
It carries a real risk of dependence and withdrawal, liver injury, seizures, and life-threatening toxicity — especially when combined with other drugs11. "Natural" does not mean safe, and it is unregulated, so product strength varies wildly.
Operation Whole Health — Patriot-founded 501(c)(3). Modality Education Library, DRAFT v0.1 — not for patient use until each brief is signed by a named licensed physician.
Disclosures & limits: Educational only; not medical advice, not a treatment protocol, and not an endorsement of any Schedule I substance or unregulated product. Substances named here carry serious, sometimes fatal risks and varying legal status; all care and clinical decisions belong to qualified treating clinicians. OWH develops nutritional prep protocols/products (conflict disclosed); this supports — never replaces — a clinic's own care and consent. Human evidence retrieved from PubMed; see references.
Crisis: dial 988, then press 1.